Overview

R-5280 in Newly Diagnosed Patients With Type 1 Diabetes

Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
Phase:
Phase 1
Details
Lead Sponsor:
Rise Therapeutics LLC